Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live BRAINTREE, Mass. , Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical ® Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY ® Endovascular Robotic System, announces that its Chief Executive Officer,
FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence Commercialization Following FDA 510(k) Clearance BRAINTREE, Mass. , Dec.
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass. , Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass. , Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 BRAINTREE, Mass. , Sept. 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional procedures between two facilities within
The ISO 13485 certification is a validation of the Company’s robust quality system BRAINTREE, Mass. , Aug. 13, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces it has received ISO 13485:2016
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system BRAINTREE, Mass. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an agreement with Emory University
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial BRAINTREE, Mass. , July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc.
